Figure 5
From: Mitochondrially targeted ceramide LCL-30 inhibits colorectal cancer in mice
(A) Progression of subcutaneous tumours in animals receiving daily injections with vehicle (open squares), doxorubicin (closed squares), LCL-30 (triangles), or LCL-30+doxorubicin (circles), *P=0.027 vs control (ANOVA); (B) Volume of explanted tumours after the end of treatment, *P<0.05, **P<0.01 vs control (ANOVA with Student–Newman-Keuls post hoc test). (C) Proliferative activity of treated tumours assessed by Ki67 immunohistochemistry, *P<0.001 vs control (ANOVA with Student–Newman-Keuls post hoc test). Results are mean±s.d. of n=8.
